| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9327711 | Gynecologic Oncology | 2005 | 8 Pages |
Abstract
The triplet combination of paclitaxel-carboplatin-gemcitabine is feasible and active, with manageable hematological toxicity and no unexpected nonhematological toxicity. This regimen has proceeded to phase III evaluation.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
A. du Bois, A. Belau, U. Wagner, J. Pfisterer, B. Schmalfeldt, B. Richter, A. Staehle, C. Jackisch, H.J. Lueck, W. Schroeder, A. Burges, S. Olbricht, G. Elser,